Blockbuster Drugmaker’s Shares Plunge 3.20% as Healthcare Sector-Wide Sell-Off Pushes ABBV to 40th in U.S. Volume Rankings

Abbvie (ABBV) closed on October 2, 2025, with a 3.20% decline, trading at a volume of $1.92 billion, a 35.08% drop from the previous day’s activity. The stock ranked 40th in trading volume among equities listed on U.S. exchanges. The move followed a mix of market dynamics and sector-specific factors impacting pharmaceutical and biotech stocks.

The broader healthcare sector faced renewed scrutiny amid regulatory developments in Europe, prompting a reevaluation of long-term growth assumptions for drugmakers. While no direct corporate announcements were cited for Abbvie’s decline, analysts noted a sector-wide pullback driven by macroeconomic concerns, including inflationary pressures and shifting investor sentiment toward high-dividend assets.

Strategic positioning for the stock remains underpinned by its portfolio of blockbuster drugs, though near-term volatility is expected to persist as investors balance near-term earnings visibility against macroeconomic risks. Institutional activity in the sector has shown a cautious stance, with fund managers adjusting exposure to align with broader market corrections.

To conduct a precise back-test of a strategy involving the 500 most-active U.S. stocks, several parameters require clarification. Key considerations include defining the stock universe (e.g., all U.S. equities or S&P 500 constituents), trade timing (intraday or overnight holding), and weighting methodologies (equal-weight vs. cost-adjusted). The feasibility of using a representative index or synthetic file for performance analysis also needs confirmation before executing the back-test.